Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure

• Published in: The New England journal of medicine Vol. 384; no. 2; pp. 105 - 116
• Main Authors: Teerlink, John R, Diaz, Rafael, Felker, G. Michael, McMurray, John J.V, Metra, Marco, Solomon, Scott D, Adams, Kirkwood F, Anand, Inder, Arias-Mendoza, Alexandra, Biering-Sørensen, Tor, Böhm, Michael, Bonderman, Diana, Cleland, John G.F, Corbalan, Ramon, Crespo-Leiro, Maria G, Dahlström, Ulf, Echeverria, Luis E, Fang, James C, Filippatos, Gerasimos, Fonseca, Cândida, Goncalvesova, Eva, Goudev, Assen R, Howlett, Jonathan G, Lanfear, David E, Li, Jing, Lund, Mayanna, Macdonald, Peter, Mareev, Viacheslav, Momomura, Shin-ichi, O’Meara, Eileen, Parkhomenko, Alexander, Ponikowski, Piotr, Ramires, Felix J.A, Serpytis, Pranas, Sliwa, Karen, Spinar, Jindrich, Suter, Thomas M, Tomcsanyi, Janos, Vandekerckhove, Hans, Vinereanu, Dragos, Voors, Adriaan A, Yilmaz, Mehmet B, Zannad, Faiez, Sharpsten, Lucie, Legg, Jason C, Varin, Claire, Honarpour, Narimon, Abbasi, Siddique A, Malik, Fady I, Kurtz, Christopher E
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 14.01.2021
• Subjects: Aged; Aged, 80 and over; Angina pectoris; Arrhythmia; Brain natriuretic peptide; Calcium-binding protein; Cardiac Myosins - drug effects; Cardiac Myosins - metabolism; Cardiology and cardiovascular system; Cardiomyopathy; Cardiotonic Agents - adverse effects; Cardiotonic Agents - pharmacology; Cardiotonic Agents - therapeutic use; Cardiovascular Diseases - mortality; Clinical medicine; Congestive heart failure; Design; Ejection fraction; Female; Heart attacks; Heart failure; Heart Failure, Systolic - drug therapy; Heart Failure, Systolic - metabolism; Heart Failure, Systolic - physiopathology; Hospitalization; Human health and pathology; Humans; Ischemia; Life Sciences; Male; Middle Aged; Myocardial Contraction - drug effects; Myosin; Patient safety; Peptides; Placebos; Statistical analysis; Stroke Volume; Troponin; Troponin I; Urea - adverse effects; Urea - analogs & derivatives; Urea - pharmacology; Urea - therapeutic use; Ventricle
• ISSN: 0028-4793; 1533-4406; 1533-4406
• DOI: 10.1056/NEJMoa2025797

Among patients with heart failure and a reduced ejection fraction, those who received the cardiac myosin activator omecamtiv mecarbil had a lower incidence of a composite of heart-failure events or cardiovascular death at a median of 22 months than those who received placebo.